Rose – Interview 17
Rose took part in a trial for people with inoperable lung cancer, comparing radiotherapy alone with radiotherapy plus chemotherapy. She had just radiotherapy. The trial was stopped early because so few people agreed to take part.
Rose found out she had lung cancer when she had a chest infection and started noticing blood in her sputum. The infection would not clear up, and when sputum samples were sent for analysis it was found she had MRSA. Although she was treated for MRSA, there was still blood in her sputum and eventually she was sent for a bronchoscopy, and she was diagnosed with lung cancer.
The plan was to operate to remove one lobe of her lung – she did not want more of the lung removed as she already had chronic obstructive pulmonary disease and did not want to restrict her breathing capacity any more than necessary. Because of the position of the tumour it turned out the surgeon could not operate after all. At this point she was invited to join the INCH trial, a trial comparing induction chemotherapy followed by Continuous Hyperfractionated Accelerated Radiotherapy (CHART) with CHART alone.
Rose felt that because these were well-established treatments, rather than anything new and experimental, she did not mind entering the trial. She was glad to be randomised to the radiotherapy alone arm, because she was not very keen on the prospect of losing her hair if she had chemotherapy as well, but would have accepted either group. She was surprised that some of the staff thought she would be disappointed not to get chemotherapy. She had twelve days of radiotherapy, with three treatments per day. She had some side effects, especially a sore throat which made eating difficult, but never thought about withdrawing from the trial.
As a former nurse, she felt she was in a better position to read and understand the information she was given better than many people, and it was obvious to her that some other people on the ward had not really understood the information given. She felt the staff were good at just explaining the trial and not trying to influence her decision either way. She did not involve any of her family in making the decision, as she believes it has to be a matter for the individual. Rose did sometimes think that because she was a nurse people assumed she did not need explanation when in fact she did. She also wondered if being in the trial meant she tended to see the research nurse rather than the doctor, on occasions when other people not in the trial might have seen a doctor.
The trial was closed early because so few people agreed to take part, and Rose’s understanding of why is that most people were unwilling to take the chance of being randomised to the group having chemotherapy. She can understand people refusing to take part in trials where very little is known about the safety and side effects of a new treatment, but cannot understand why people were reluctant to join this trial. As it turns out, her lung cancer has returned and she is likely to end up having chemotherapy anyway. Rose herself would be reluctant to join a trial of a very new treatment unless she was so ill that she had few treatment choices left. She would be thinking it might benefit her granddaughter’s generation, even if she might not benefit herself.